A. Garrido-Castro

Oncology · 2017–2019

A researcher in the Science corpus: 2 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom A. Garrido-Castro trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Mark E. Robson
  2. D. Pardoll

Papers from A. Garrido-Castro's perspective

Ordered by how strongly the researchers A. Garrido-Castro trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy (Nature)
  2. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. (Journal of Clinical Investigation)
  3. The clonal and mutational evolution spectrum of primary triple-negative breast cancers (Nature)
  4. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. (Journal of Clinical Oncology)
  5. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  6. Mutational Processes Molding the Genomes of 21 Breast Cancers (Cell)
  7. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  8. The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin*
  9. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups (Nature)
  10. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)

Their papers